{"data":{"ModuleTitle":{"label":"Module Title","value":"Company Description"},"CompanyName":{"label":"Company Name","value":"NextCure, Inc."},"Symbol":{"label":"Symbol","value":"NXTC"},"Address":{"label":"Address","value":"9000 VIRGINIA MANOR ROAD,SUITE 200, BELTSVILLE, Maryland, 20705, United States"},"Phone":{"label":"Phone","value":"+1 240 399-4900"},"Industry":{"label":"Industry","value":"Biotechnology: Pharmaceutical Preparations"},"Sector":{"label":"Sector","value":"Health Care"},"Region":{"label":"Region","value":"North America"},"CompanyDescription":{"label":"Company Description","value":"NextCure Inc is a clinical-stage biopharmaceutical company committed to discovering and developing immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. It is focused on understanding biological pathways, the interactions of cells and the role each interaction plays in an immune response. The company's product candidate, NC318, is an immunomedicine against an immunomodulatory receptor called Siglec-15, or S15."},"CompanyUrl":{"label":"Company Url","value":"https://www.nextcure.com"},"KeyExecutives":{"label":"Key Executives","value":[{"name":"Solomon Langermann","title":"Chief Scientific Officer"},{"name":"Timothy Mayer","title":"Chief Operating Officer"},{"name":"Udayan Guha","title":"Senior VP-Clinical & Translational Development"}]}},"message":null,"status":{"rCode":200,"bCodeMessage":null,"developerMessage":null}}